Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 877-883

  Teng, Renli ^a   Mitchell, Patrick ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Drug drug interaction; P2Y12 receptor antagonist; Pharmacokinetics; Rifampicin; Ticagrelor

Indexed keywords

AR C 124910XX; CYTOCHROME P450 3A; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN; PURINERGIC P2Y12 RECEPTOR; RECEPTOR BLOCKING AGENT; RIFAMPICIN; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; COUGHING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRY THROAT; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; LARYNX PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE OBSTRUCTION; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SORE THROAT; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA;

ADENOSINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RIFAMPIN; YOUNG ADULT;

EID: 84876713253     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1436-x     Document Type: Article

References (29)

1. 12 receptor antagonist. Cardiovasc Ther 27:259-274
2. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038-1047
3. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50:1852-1856
4. Brilique, summary of product characteristics, 2010. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001241/ WC500100494.pdf. Accessed 30 January 2012
5. Brilinta™, US full prescribing information, July 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s000lbl.pdf. Accessed 30 January 2012
6. Butler K, Teng R (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 70:65-77
7. 12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects. Can J Clin Pharmacol 15:e426
8. 12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 66:487-496
9. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. J Thromb Haemost 72:313-317
10. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:556-565
11. Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T (2010) Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos 38:898-904
12. Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514-1521
13. van Giezen JJJ (2008) Optimizing platelet inhibition. Eur Heart J 10(suppl D):D23-D29
14. Zhou D, Andersson TB, Grimm SW (2011) In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome p450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 39:703-710
15. Sousa M, Pozniak A, Boffito M (2008) Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 62:872-878
16. Backman JT, Granfors MT, Neuvonen PJ (2006) Rifampin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62:451-461
17. Raybon JJ, Pray D, Morgan DG, Zoeckler M, Zheng M, Sinz M, Kim S (2011) Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice. J Pharmacol Exp Ther 337:75-82
18. Daujat M, Clair P, Astier C, Pineau T, Yerle M, Gellin J, Maurel P (1991) Induction, regulation and messenger half-life of cytochromes P450 IA1, IA2 and IIIA6 in primary cultures of rabbit hepatocytes. CYP 1A1, 1A2 and 3A6 chromosome location in the rabbit and evidence that post-transcriptional control of gene IA2 does not involve mRNA stabilization. Eur J Biochem 200:501-510
19. Food and Drug Administration. Guidance for industry: Drug interaction studies - study design, data analysis and implications for dosing and labeling. Sep 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed 30 January 2012
20. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819-850
21. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A (2011) Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234-242
22. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 116:e148-e304
23. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W, Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
24. Sillén H, Cook M, Davis P (2010) Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2299-2306
25. Meen Ø, Brosstad F, Bjørnsen S, Pedersen TM, Erikssen G (2009) Variability in aggregometry response before and after initiation of clopidogrel therapy. Scand J Clin Lab Invest 69(6):673-679
26. Labarthe J, Théroux P, Angioï M, Ghitescu M (2005) Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46:638-645
27. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256
28. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50:1844-1851
29. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057.